The very recent ADA/EASD guideline [10,18] suggests that in patients with T2D with established or having a high risk for atherosclerotic cardiovascular disease and chronic kidney disease, GLP-1 RAs with demonstrated cardiovascular benefit are recommended, even independent of baseline HbA1C. Here, GLP1R is linked to chronic kidney disease.